Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stock Competitors & Peer Comparison
See INO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INO | $0.60 | -21.95% | 41.5M | -0.52 | -$1.16 | N/A |
| VRTX | $558.88 | +3.50% | 141.7B | 29.37 | $19.03 | N/A |
| REGN | $927.89 | +13.33% | 95.5B | 20.32 | $45.63 | +0.40% |
| MRNA | $221.72 | -0.47% | 88.5B | -27.19 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $892.87 | -0.55% | 54.8B | 32.19 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.81 | +1.82% | 41.8B | -1.12 | -$8.82 | N/A |
| RVMD | $191.31 | +0.55% | 41B | -21.69 | -$8.82 | N/A |
| ONC | $370.33 | -0.33% | 39.6B | 65.20 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
INO vs VRTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, VRTX has a market cap of 141.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while VRTX trades at $558.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas VRTX's P/E ratio is 29.37. In terms of profitability, INO's ROE is -10.06%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, INO is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
INO vs REGN Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, REGN has a market cap of 95.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while REGN trades at $927.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas REGN's P/E ratio is 20.32. In terms of profitability, INO's ROE is -10.06%, compared to REGN's ROE of +0.15%. Regarding short-term risk, INO is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for INO.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
INO vs MRNA Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, MRNA has a market cap of 88.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while MRNA trades at $221.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas MRNA's P/E ratio is -27.19. In terms of profitability, INO's ROE is -10.06%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, INO is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for INO.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
INO vs VRNA Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas VRNA's P/E ratio is -102.80. In terms of profitability, INO's ROE is -10.06%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, INO is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for INO.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
INO vs ARGX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ARGX has a market cap of 54.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ARGX trades at $892.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ARGX's P/E ratio is 32.19. In terms of profitability, INO's ROE is -10.06%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, INO is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for INO.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
INO vs SGEN Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas SGEN's P/E ratio is -57.19. In terms of profitability, INO's ROE is -10.06%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, INO is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for INO.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
INO vs RVMDW Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while RVMDW trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas RVMDW's P/E ratio is -1.12. In terms of profitability, INO's ROE is -10.06%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, INO is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for INO.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
INO vs RVMD Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while RVMD trades at $191.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas RVMD's P/E ratio is -21.69. In terms of profitability, INO's ROE is -10.06%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, INO is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for INO.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
INO vs ONC Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ONC has a market cap of 39.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ONC trades at $370.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ONC's P/E ratio is 65.20. In terms of profitability, INO's ROE is -10.06%, compared to ONC's ROE of +0.14%. Regarding short-term risk, INO is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for INO.Check ONC's competition here
Genmab A/S (NASDAQ: GMAB)
INO vs GMAB Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, GMAB has a market cap of 34.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while GMAB trades at $57.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas GMAB's P/E ratio is 42.57. In terms of profitability, INO's ROE is -10.06%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, INO is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for INO.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
INO vs ROIV Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ROIV has a market cap of 26.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ROIV trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ROIV's P/E ratio is -35.10. In terms of profitability, INO's ROE is -10.06%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, INO is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for INO.Check ROIV's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
INO vs UTHR Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, UTHR has a market cap of 25.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while UTHR trades at $598.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas UTHR's P/E ratio is 21.42. In terms of profitability, INO's ROE is -10.06%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, INO is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for INO.Check UTHR's competition here
Insmed Incorporated (NASDAQ: INSM)
INO vs INSM Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, INSM has a market cap of 24.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while INSM trades at $112.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas INSM's P/E ratio is -27.40. In terms of profitability, INO's ROE is -10.06%, compared to INSM's ROE of -0.83%. Regarding short-term risk, INO is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for INO.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
INO vs INCY Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while INCY trades at $120.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas INCY's P/E ratio is 16.18. In terms of profitability, INO's ROE is -10.06%, compared to INCY's ROE of +0.07%. Regarding short-term risk, INO is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for INO.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
INO vs ALNY Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ALNY has a market cap of 22B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ALNY trades at $165.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ALNY's P/E ratio is 29.68. In terms of profitability, INO's ROE is -10.06%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, INO is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for INO.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
INO vs BNTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, BNTX has a market cap of 21.9B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while BNTX trades at $88.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas BNTX's P/E ratio is -11.43. In terms of profitability, INO's ROE is -10.06%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, INO is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
INO vs BGNE Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas BGNE's P/E ratio is -22.55. In terms of profitability, INO's ROE is -10.06%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, INO is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for INO.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
INO vs DNA-WT Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, INO's ROE is -10.06%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, INO is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for INO.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
INO vs EXEL Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, EXEL has a market cap of 17.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while EXEL trades at $69.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas EXEL's P/E ratio is 19.83. In terms of profitability, INO's ROE is -10.06%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, INO is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for INO.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
INO vs ASND Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ASND trades at $251.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ASND's P/E ratio is -103.74. In terms of profitability, INO's ROE is -10.06%, compared to ASND's ROE of +1.90%. Regarding short-term risk, INO is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for INO.Check ASND's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
INO vs HALO Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, HALO has a market cap of 14.9B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while HALO trades at $130.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas HALO's P/E ratio is 24.43. In terms of profitability, INO's ROE is -10.06%, compared to HALO's ROE of +1.81%. Regarding short-term risk, INO is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for INO.Check HALO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
INO vs NBIX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, NBIX has a market cap of 14.9B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while NBIX trades at $146.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas NBIX's P/E ratio is 21.11. In terms of profitability, INO's ROE is -10.06%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, INO is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for INO.Check NBIX's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
INO vs BBIO Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, BBIO has a market cap of 14.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while BBIO trades at $74.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas BBIO's P/E ratio is -20.04. In terms of profitability, INO's ROE is -10.06%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, INO is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for INO.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
INO vs JAZZ Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, JAZZ has a market cap of 14B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while JAZZ trades at $215.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas JAZZ's P/E ratio is 8.05. In terms of profitability, INO's ROE is -10.06%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, INO is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for INO.Check JAZZ's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
INO vs SMMT Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, SMMT has a market cap of 12.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while SMMT trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas SMMT's P/E ratio is -14.31. In terms of profitability, INO's ROE is -10.06%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, INO is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for INO.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
INO vs KRTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas KRTX's P/E ratio is -28.09. In terms of profitability, INO's ROE is -10.06%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, INO is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
INO vs TECH Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while TECH trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas TECH's P/E ratio is 37.46. In terms of profitability, INO's ROE is -10.06%, compared to TECH's ROE of +0.09%. Regarding short-term risk, INO is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for INO.Check TECH's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
INO vs BMRN Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while BMRN trades at $58.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas BMRN's P/E ratio is 28.14. In terms of profitability, INO's ROE is -10.06%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, INO is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for INO.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
INO vs RNAM Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas RNAM's P/E ratio is -17.39. In terms of profitability, INO's ROE is -10.06%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, INO is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for INO.Check RNAM's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
INO vs KYMR Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, KYMR has a market cap of 10.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while KYMR trades at $126.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas KYMR's P/E ratio is -39.58. In terms of profitability, INO's ROE is -10.06%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, INO is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for INO.Check KYMR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
INO vs TWST Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, TWST has a market cap of 10.1B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while TWST trades at $152.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas TWST's P/E ratio is -68.83. In terms of profitability, INO's ROE is -10.06%, compared to TWST's ROE of -0.30%. Regarding short-term risk, INO is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for INO.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
INO vs MDGL Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while MDGL trades at $430.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas MDGL's P/E ratio is -33.62. In terms of profitability, INO's ROE is -10.06%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, INO is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for INO.Check MDGL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
INO vs KRYS Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while KRYS trades at $332.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas KRYS's P/E ratio is 41.60. In terms of profitability, INO's ROE is -10.06%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, INO is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for INO.Check KRYS's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
INO vs PCVX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, PCVX has a market cap of 9.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while PCVX trades at $62.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas PCVX's P/E ratio is -8.13. In terms of profitability, INO's ROE is -10.06%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, INO is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for INO.Check PCVX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
INO vs CAI Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CAI has a market cap of 9.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CAI trades at $34.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CAI's P/E ratio is 96.46. In terms of profitability, INO's ROE is -10.06%, compared to CAI's ROE of +0.19%. Regarding short-term risk, INO is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for INO.Check CAI's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
INO vs RXDX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas RXDX's P/E ratio is -56.47. In terms of profitability, INO's ROE is -10.06%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, INO is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for INO.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
INO vs PTGX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while PTGX trades at $144.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas PTGX's P/E ratio is 140.75. In terms of profitability, INO's ROE is -10.06%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, INO is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for INO.Check PTGX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
INO vs TGTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, TGTX has a market cap of 9.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while TGTX trades at $61.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas TGTX's P/E ratio is 22.17. In terms of profitability, INO's ROE is -10.06%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, INO is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check TGTX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
INO vs NUVL Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas NUVL's P/E ratio is -21.79. In terms of profitability, INO's ROE is -10.06%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, INO is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for INO.Check NUVL's competition here
10x Genomics, Inc. (NASDAQ: TXG)
INO vs TXG Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, TXG has a market cap of 9.1B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while TXG trades at $70.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas TXG's P/E ratio is -118.82. In terms of profitability, INO's ROE is -10.06%, compared to TXG's ROE of -0.09%. Regarding short-term risk, INO is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for INO.Check TXG's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
INO vs CRNX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CRNX's P/E ratio is -16.86. In terms of profitability, INO's ROE is -10.06%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, INO is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for INO.Check CRNX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
INO vs SYRE Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, SYRE has a market cap of 8.9B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while SYRE trades at $96.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas SYRE's P/E ratio is -49.54. In terms of profitability, INO's ROE is -10.06%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, INO is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for INO.Check SYRE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
INO vs IBRX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while IBRX trades at $8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas IBRX's P/E ratio is -8.54. In terms of profitability, INO's ROE is -10.06%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, INO is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for INO.Check IBRX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
INO vs CYTK Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CYTK has a market cap of 8.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CYTK trades at $62.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CYTK's P/E ratio is -8.72. In terms of profitability, INO's ROE is -10.06%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, INO is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for INO.Check CYTK's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
INO vs IMGN Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas IMGN's P/E ratio is -111.55. In terms of profitability, INO's ROE is -10.06%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, INO is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for INO.Check IMGN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
INO vs ARWR Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ARWR has a market cap of 8.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ARWR trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ARWR's P/E ratio is -26.61. In terms of profitability, INO's ROE is -10.06%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, INO is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for INO.Check ARWR's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
INO vs APGE Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas APGE's P/E ratio is -31.19. In terms of profitability, INO's ROE is -10.06%, compared to APGE's ROE of -0.30%. Regarding short-term risk, INO is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for INO.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
INO vs BPMC Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas BPMC's P/E ratio is -51.58. In terms of profitability, INO's ROE is -10.06%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, INO is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for INO.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
INO vs CERE Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CERE's P/E ratio is -16.47. In terms of profitability, INO's ROE is -10.06%, compared to CERE's ROE of -0.72%. Regarding short-term risk, INO is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for INO.Check CERE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
INO vs PRAX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, PRAX has a market cap of 8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while PRAX trades at $285.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas PRAX's P/E ratio is -22.10. In terms of profitability, INO's ROE is -10.06%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, INO is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for INO.Check PRAX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
INO vs AXSM Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, AXSM has a market cap of 7.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while AXSM trades at $144.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas AXSM's P/E ratio is -37.77. In terms of profitability, INO's ROE is -10.06%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, INO is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for INO.Check AXSM's competition here
Abivax S.A. (NASDAQ: ABVX)
INO vs ABVX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ABVX has a market cap of 7.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ABVX trades at $86.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ABVX's P/E ratio is -14.19. In terms of profitability, INO's ROE is -10.06%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, INO is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for INO.Check ABVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
INO vs MTSR Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas MTSR's P/E ratio is -23.58. In terms of profitability, INO's ROE is -10.06%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, INO is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for INO.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
INO vs IONS Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while IONS trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas IONS's P/E ratio is -13.31. In terms of profitability, INO's ROE is -10.06%, compared to IONS's ROE of -1.11%. Regarding short-term risk, INO is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for INO.Check IONS's competition here
Merus N.V. (NASDAQ: MRUS)
INO vs MRUS Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas MRUS's P/E ratio is -17.05. In terms of profitability, INO's ROE is -10.06%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, INO is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for INO.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
INO vs ACLX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ACLX's P/E ratio is -28.27. In terms of profitability, INO's ROE is -10.06%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, INO is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for INO.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
INO vs RETA Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas RETA's P/E ratio is -66.29. In terms of profitability, INO's ROE is -10.06%, compared to RETA's ROE of +0.47%. Regarding short-term risk, INO is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for INO.Check RETA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
INO vs LGND Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, LGND has a market cap of 6.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while LGND trades at $322.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas LGND's P/E ratio is 35.42. In terms of profitability, INO's ROE is -10.06%, compared to LGND's ROE of +0.05%. Regarding short-term risk, INO is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for INO.Check LGND's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
INO vs ORKA Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ORKA has a market cap of 6.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ORKA trades at $96.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ORKA's P/E ratio is -49.92. In terms of profitability, INO's ROE is -10.06%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, INO is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for INO.Check ORKA's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
INO vs RYTM Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while RYTM trades at $92.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas RYTM's P/E ratio is -29.78. In terms of profitability, INO's ROE is -10.06%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, INO is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for INO.Check RYTM's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
INO vs CNTA Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CNTA's P/E ratio is -22.63. In terms of profitability, INO's ROE is -10.06%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, INO is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for INO.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
INO vs KOD Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while KOD trades at $99.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas KOD's P/E ratio is -23.78. In terms of profitability, INO's ROE is -10.06%, compared to KOD's ROE of -2.73%. Regarding short-term risk, INO is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for INO.Check KOD's competition here
Belite Bio, Inc (NASDAQ: BLTE)
INO vs BLTE Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while BLTE trades at $154.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas BLTE's P/E ratio is -82.96. In terms of profitability, INO's ROE is -10.06%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, INO is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for INO.Check BLTE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
INO vs TERN Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas TERN's P/E ratio is -51.41. In terms of profitability, INO's ROE is -10.06%, compared to TERN's ROE of -0.14%. Regarding short-term risk, INO is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for INO.Check TERN's competition here
Immunovant, Inc. (NASDAQ: IMVT)
INO vs IMVT Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, IMVT has a market cap of 6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while IMVT trades at $29.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas IMVT's P/E ratio is -10.34. In terms of profitability, INO's ROE is -10.06%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, INO is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for INO.Check IMVT's competition here
Veradermics, Incorporated (NYSE: MANE)
INO vs MANE Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while MANE trades at $139.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas MANE's P/E ratio is -44.48. In terms of profitability, INO's ROE is -10.06%, compared to MANE's ROE of -0.38%. Regarding short-term risk, INO is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for INO.Check MANE's competition here
CG Oncology Inc. (NASDAQ: CGON)
INO vs CGON Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CGON trades at $64.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CGON's P/E ratio is -23.98. In terms of profitability, INO's ROE is -10.06%, compared to CGON's ROE of -0.25%. Regarding short-term risk, INO is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for INO.Check CGON's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
INO vs CDTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CDTX's P/E ratio is -19.77. In terms of profitability, INO's ROE is -10.06%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, INO is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
INO vs ABCM Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, INO's ROE is -10.06%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, INO is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for INO.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
INO vs ISEE Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ISEE's P/E ratio is -22.44. In terms of profitability, INO's ROE is -10.06%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, INO is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for INO.Check ISEE's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
INO vs MIRM Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while MIRM trades at $85.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas MIRM's P/E ratio is -5.83. In terms of profitability, INO's ROE is -10.06%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, INO is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for INO.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
INO vs COGT Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while COGT trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas COGT's P/E ratio is -14.69. In terms of profitability, INO's ROE is -10.06%, compared to COGT's ROE of -0.73%. Regarding short-term risk, INO is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for INO.Check COGT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
INO vs SRRK Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while SRRK trades at $43.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas SRRK's P/E ratio is -12.72. In terms of profitability, INO's ROE is -10.06%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, INO is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for INO.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
INO vs APLS Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas APLS's P/E ratio is 38.35. In terms of profitability, INO's ROE is -10.06%, compared to APLS's ROE of +0.40%. Regarding short-term risk, INO is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for INO.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
INO vs ERAS Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ERAS trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ERAS's P/E ratio is -15.41. In terms of profitability, INO's ROE is -10.06%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, INO is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for INO.Check ERAS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
INO vs PTCT Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, PTCT has a market cap of 5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while PTCT trades at $59.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas PTCT's P/E ratio is -25.73. In terms of profitability, INO's ROE is -10.06%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, INO is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for INO.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
INO vs CRSP Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CRSP trades at $51.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CRSP's P/E ratio is -10.80. In terms of profitability, INO's ROE is -10.06%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, INO is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for INO.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
INO vs DFTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while DFTX trades at $36.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas DFTX's P/E ratio is N/A. In terms of profitability, INO's ROE is -10.06%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, INO is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check DFTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
INO vs TVTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, TVTX has a market cap of 4.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while TVTX trades at $50.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas TVTX's P/E ratio is -111.98. In terms of profitability, INO's ROE is -10.06%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, INO is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
INO vs DNTH Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while DNTH trades at $82.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas DNTH's P/E ratio is -19.87. In terms of profitability, INO's ROE is -10.06%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, INO is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for INO.Check DNTH's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
INO vs FOLD Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas FOLD's P/E ratio is -161.00. In terms of profitability, INO's ROE is -10.06%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, INO is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for INO.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
INO vs AKRO Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas AKRO's P/E ratio is -14.57. In terms of profitability, INO's ROE is -10.06%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, INO is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for INO.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
INO vs ALPN Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ALPN's P/E ratio is -101.52. In terms of profitability, INO's ROE is -10.06%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, INO is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for INO.Check ALPN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
INO vs ADPT Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ADPT trades at $26.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ADPT's P/E ratio is -64.93. In terms of profitability, INO's ROE is -10.06%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, INO is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for INO.Check ADPT's competition here
Opthea Limited (NASDAQ: OPT)
INO vs OPT Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas OPT's P/E ratio is -1.52. In terms of profitability, INO's ROE is -10.06%, compared to OPT's ROE of +1.18%. Regarding short-term risk, INO is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for INO.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
INO vs PRTC Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas PRTC's P/E ratio is -3.78. In terms of profitability, INO's ROE is -10.06%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, INO is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for INO.Check PRTC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
INO vs EWTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while EWTX trades at $38.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas EWTX's P/E ratio is -21.03. In terms of profitability, INO's ROE is -10.06%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, INO is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
INO vs MRTX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas MRTX's P/E ratio is -4.82. In terms of profitability, INO's ROE is -10.06%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, INO is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for INO.Check MRTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
INO vs ARQT Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ARQT has a market cap of 4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ARQT trades at $32.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ARQT's P/E ratio is 152.62. In terms of profitability, INO's ROE is -10.06%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, INO is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for INO.Check ARQT's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
INO vs RLAY Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while RLAY trades at $18.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas RLAY's P/E ratio is -11.68. In terms of profitability, INO's ROE is -10.06%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, INO is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for INO.Check RLAY's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
INO vs LEGN Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while LEGN trades at $21.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas LEGN's P/E ratio is -31.79. In terms of profitability, INO's ROE is -10.06%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, INO is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for INO.Check LEGN's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
INO vs ABCL Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, ABCL has a market cap of 4B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while ABCL trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas ABCL's P/E ratio is -22.71. In terms of profitability, INO's ROE is -10.06%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, INO is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for INO.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
INO vs CPRX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CPRX's P/E ratio is 17.49. In terms of profitability, INO's ROE is -10.06%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, INO is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for INO.Check CPRX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
INO vs IOVA Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while IOVA trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas IOVA's P/E ratio is -11.60. In terms of profitability, INO's ROE is -10.06%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, INO is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for INO.Check IOVA's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
INO vs TNGX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while TNGX trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas TNGX's P/E ratio is -27.37. In terms of profitability, INO's ROE is -10.06%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, INO is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for INO.Check TNGX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
INO vs RYZB Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas RYZB's P/E ratio is -57.86. In terms of profitability, INO's ROE is -10.06%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, INO is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for INO.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
INO vs CBAY Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas CBAY's P/E ratio is -32.81. In terms of profitability, INO's ROE is -10.06%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, INO is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for INO.Check CBAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
INO vs XENE Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, XENE has a market cap of 3.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while XENE trades at $37.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas XENE's P/E ratio is -7.96. In terms of profitability, INO's ROE is -10.06%, compared to XENE's ROE of -0.44%. Regarding short-term risk, INO is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for INO.Check XENE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
INO vs AMLX Comparison November 2026
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INO stands at 41.5M. In comparison, AMLX has a market cap of 3.6B. Regarding current trading prices, INO is priced at $0.60 on the NASDAQ, while AMLX trades at $28.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INO currently has a P/E ratio of -0.52, whereas AMLX's P/E ratio is -19.24. In terms of profitability, INO's ROE is -10.06%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, INO is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for INO.Check AMLX's competition here